

# INFECTION CONTROL



## *The Pathogenesis and Epidemiology of *Klebsiella pneumoniae**

---

### **EDITORIAL**

#### **The Pathogenesis and Epidemiology of *Klebsiella pneumoniae*, Symposium Introduction**

John E. McGowan, Jr., MD

### **ORIGINAL ARTICLES**

#### **Habitat Association of *Klebsiella* Species**

Susan T. Bagley, PhD

#### ***Klebsiella* Marker Systems**

Sally Jo Rubin, PhD

#### **Resistance to Antibiotics in Clinical Isolates of *Klebsiella pneumoniae***

Thomas F. O'Brien, MD; Kenneth H. Mayer, MD; John D. Hopkins, PhD;  
John J. Farrell, BA; Lee Chao, MS; Ralph L. Kent, DSc

#### **The Epidemiology of Nosocomial Infections Caused by *Klebsiella pneumoniae***

William R. Jarvis, MD; Van P. Munn; Anita K. Highsmith;  
David H. Culver, PhD; James M. Hughes, MD

#### ***Klebsiella pneumoniae*: Selected Virulence Factors that Contribute to Pathogenicity**

Anita K. Highsmith; William R. Jarvis, MD

#### **Clinical Pharmacology of Antibiotics: The Cephalosporin Antibiotic Agents— III. Third-Generation Cephalosporins**

T. Donald Marsh, PharmD

#### **Infection Control and Employee Health: Update on AIDS**

William M. Valenti, MD

# NEOTEC <sup>I<sub>2</sub></sup>

## Provides the 4 Most-Desired Benefits

### Efficacy...



### Mildness...



#### **NEOTEC: Highly Effective Antiseptic Handwash**

NEOTEC Antiseptic Handwash employs the revolutionary new concept of low-iodine technology to provide 4 to 5 times the amount of free iodine — the "major bactericidal agent" — as in existing povidone-iodine solutions. NEOTEC has a rapid bactericidal effect against a wide range of organisms typically encountered in high-risk areas of the hospital?

#### **NEOTEC: Less Irritating Antiseptic Handwash**

NEOTEC Antiseptic Handwash combines high efficacy with the mildness required by nurses and physicians who must wash their hands often every day. In a direct-comparison evaluation, NEOTEC caused no irritation or allergic reactions, whereas 25% of the subjects using a 10% povidone-iodine solution had adverse reactions? Thus, NEOTEC is ideal for use in the ER, ICU, CCU, nursery, or wherever high-risk procedures are routinely performed.

# of an Antiseptic Handwash

## Non-Staining...

## Economy



### **NEOTEC: Non-Staining Antiseptic Handwash**

NEOTEC Antiseptic Handwash works itself into a pure white, non-staining lather that won't discolor skin or uniform. Concentrated NEOTEC washes right out of clothing.

### **NEOTEC: Highly Economical Antiseptic Handwash**

NEOTEC fits any hospital cost-containment or DRG program because it's less expensive than other antiseptic handwashes presently on the market. Foot-operated NEOTEC dispensers are available. Specify NEOTEC for use in all high-risk areas of the hospital where you require an effective, mild, non-staining, economical antiseptic handwash.

(1) Anderson RL, Berkelman RL and Holland BW, "Microbiologic Investigations with Iodophor Solutions," Centers for Disease Control, Atlanta, Georgia.

(2) "Minimum inhibitory concentrations of a low iodine formulation against microorganisms," Final Report #8401-09-002D, March 22, 1984, Skyland Scientific Services, Inc., report on file.

(3) "Efficacy evaluation of low iodine formulation in a health care personnel handwash," Final Report #8401-09-001D, April 3, 1984, Skyland Scientific Services, Inc., report on file.

## **DOW B. HICKAM, INC.**

Pharmaceuticals  
P.O. Box 2006  
Sugar Land, Texas 77478  
(713) 240-1000



# Safe for Scopes



## HEPATITIS

**Sporicidin, diluted 1:16, inactivates the Hepatitis B Virus in 10 minutes.**

*(Centers for Disease Control, Phoenix, Arizona)*

Courtesy of Olympus and ACMI

**Completely disinfects flexible and rigid scopes in 10 minutes with only 0.13% glutaraldehyde.**

**Safe to use . . .** Does not cloud scope lenses nor harm metals, rubber and/or plastics. Does not stain or irritate the hands. No gloves are necessary for safety. Vapors do not irritate the eyes or nostrils.

**Most effective . . .** The only sterilizing solution which is fully effective against the tubercle bacillus, influenza, hepatitis and enteroviruses when diluted 1 in 16.

**Stable . . .** Fully effective for 30 days after activation.

**Proven . . . The most effective cold sterilant and disinfectant ever registered by the E.P.A.**

**"Sporicidin, diluted 1 in 16, (0.13% glutaraldehyde), is effective for high level hospital disinfection . . ."**

*Centers for Disease Control, Atlanta, GA  
(Guidelines . . . revised August 1982)*

**"This study has determined that although E.P.A. requirements for classifying a sterilizing agent were satisfied by Cidex, they were exceeded by Sporicidin . . ."**

*Journal of Dental Research, Vol. 60, March 1981  
(U.S. Army Institute of Dental Research, Wash., DC)*

**"Sporicidin . . . was both more stable and more active against test spores than . . . Cidex and Cidex-7."**

*Infection Control, 1(2): 90-93, 1980*



**The Sporicidin Company**

4000 Massachusetts Avenue, NW, Washington, DC 20016 Call Toll Free (800) 424-3733

# INFECTION CONTROL

## Table of Contents

### Editorial

- The Pathogenesis and Epidemiology of *Klebsiella pneumoniae*,  
Symposium Introduction** 51  
John E. McGowan, Jr., MD

### Original Articles

- Habitat Association of *Klebsiella* Species** 52  
Susan T. Bagley, PhD

- Klebsiella* Marker Systems** 59  
Sally Jo Rubin, PhD

- Resistance to Antibiotics in Clinical Isolates of  
*Klebsiella pneumoniae*** 64  
Thomas F. O'Brien, MD; Kenneth H. Mayer, MD;  
John D. Hopkins, PhD; John J. Farrell, BA;  
Lee Chao, MS; Ralph L. Kent, DSc

- The Epidemiology of Nosocomial Infections  
Caused by *Klebsiella pneumoniae*** 68  
William R. Jarvis, MD; Van P. Munn; Anita K. Highsmith;  
David H. Culver, PhD; James M. Hughes, MD

- Klebsiella pneumoniae*: Selected Virulence Factors  
that Contribute to Pathogenicity** 75  
Anita K. Highsmith; William R. Jarvis, MD

- Clinical Pharmacology of Antibiotics:  
The Cephalosporin Antibiotic Agents—  
III. Third-Generation Cephalosporins** 78  
T. Donald Marsh, PharmD

- Infection Control and Employee Health:  
Update on AIDS** 85  
William M. Valenti, MD

### Departments

- Letters to the Editor** 50                      **Calendar of Events** 88  
**Book Reviews** 87

---

The ideas and opinions expressed by contributing authors do not  
necessarily reflect those of the editors or publisher.

---

**Publisher:** Infection Control (ISSN-0195-9417) is published monthly by SLACK Incorporated, 6900 Grove Road, Thorofare, New Jersey 08086. Telephone: Thorofare (609) 848-1000.


**Copyright 1985:** All rights reserved. No part of this publication may be reproduced without written permission from the publisher.

**Subscriptions:** Subscription requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Scope Incorporated, 11-11, Shoto 2-chrome, Shibuya-Ku, Tokyo 150, Japan. Annual subscription price is: Individual: One year—\$35.00; Two years—\$60.00; Three years—\$75.00. Institutional: One year—\$50.00; Two years—\$75.00; Three years—\$90.00. All subscriptions, without exception, will start with the first issue published after the order is received. Back copies are available, but must be purchased separately. Cost per individual copy is \$5.00. Foreign subscribers add \$15.00 to regular rate: foreign orders, \$7.00.

**Change of address:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086.  
**Postmaster:** Form 3547 to SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086.

As of Volume 1, Number 1, INFECTION CONTROL is listed in *Index Medicus*, *Current Contents—Clinical Practice*, *Hospital Literature Index*, and *Cumulative Index to Nursing and Allied Health Literature*.

# The Mediscus Mark $\nabla$ -A Pressure Treatment System ...



## INNOVATIVE


The Mediscus Mark  $\nabla$ -A Pressure Treatment System is an innovative and effective approach to preventing and treating pressure sores. With its temperature controlled air pressure system, the patient is cared for on 21 pliable, vapor permeable, yet waterproof sacs. These sacs are arranged in five sections, each with its own pressure control dial and pressure gauge.

- The air flowing through the vapor permeable air sacs dries exudate, removing a breeding ground for bacteria, without dehydrating the patient.
- Draw sheets, made of the same material as the air sacs, protect the underlying air sacs from excessive ointments, drainage and perspiration.
- The polyurethane-coated nylon air sacs and draw sheets can easily be removed from the bed and laundered, disinfected and sterilized using standard hospital procedures.

## COST EFFECTIVE

The minimal surface pressure of the Mark  $\nabla$ -A decreases complications of immobilized patients and eliminates factors that retard the healing process, resulting in more rapid healing of wounds and decreased hospital stays. Nursing hours are saved because it is not necessary to turn patients for pressure relief.

The Mediscus Mark  $\nabla$ -A Pressure Treatment System and accessories are available through local distributors for **RENTAL** or **PURCHASE**. For more information **Call Toll Free 1-800-922-9065**  
**In Texas Call 1-713-583-9232.**



**Mediscus Products, Inc.**  
13135 Champions Drive, Suite 120  
Houston, Texas 77069  
800-922-9065 Telex: 820-736  
In Texas Call 713-583-9232

## EDITOR

**Richard P. Wenzel, MD**  
Charlottesville, Virginia

## SENIOR ASSOCIATE EDITOR

**William Schaffner, MD**  
Nashville, Tennessee

## ASSOCIATE EDITORS

**Sue Crow, RN, MSN**  
Shreveport, Louisiana

**John E. McGowan, Jr., MD**  
Atlanta, Georgia

**Dennis G. Maki, MD**  
Madison, Wisconsin



SLACK Incorporated  
6900 Grove Road  
Thorofare, New Jersey 08086

## Publisher

Richard N. Roash

## Managing Editor

Donna Carpenter

## Consulting Editor

Eric Baloff

## Assistant Editor

Linda L. Jones

## Circulation Manager

Kevin J. Fenton

## Advertising Manager

Melissa Warner

## Advertising

## Sales Representative

Wayne McCourt

## Classified

## Advertising Representative

Lorraine Giles

## EDITORIAL

### ADVISORY BOARD

Robert C. Aber, MD  
Hershey, Pennsylvania

Charles S. Bryan, MD  
Columbia, South Carolina

John P. Burke, MD  
Salt Lake City, Utah

Marie B. Coyle, PhD  
Seattle, Washington

Burke A. Cunha, MD  
Mineola, New York

Richard E. Dixon, MD  
Trenton, New Jersey

Harvey A. Elder, MD  
Loma Linda, California

Bruce Farber, MD  
Pittsburgh, Pennsylvania

Peter C. Fuchs, MD, PhD  
Portland, Oregon

Richard A. Garibaldi, MD  
Farmington, Connecticut

Donald A. Goldmann, MD  
Boston, Massachusetts

Dieter H.M. Gröschel, MD  
Charlottesville, Virginia

Peter A. Gross, MD  
Hackensack, New Jersey

Karen Hadley, RN, MPH  
New Orleans, Louisiana

David K. Henderson, MD  
Bethesda, Maryland

Peter N.R. Heseltine, MD  
Los Angeles, California

Cyrus C. Hopkins, MD  
Boston, Massachusetts

Allen B. Kaiser, MD  
Nashville, Tennessee

Harold Laufman, MD, PhD  
New York, New York

William J. Ledger, MD  
New York, New York

Barbara McArthur, RN, PhD  
Detroit, Michigan

Rob Roy MacGregor, MD  
Philadelphia, Pennsylvania

C. Glen Mayhall, MD  
Richmond, Virginia

Ronald Lee Nichols, MD  
New Orleans, Louisiana

Harry C. Nottebart, Jr., JD, MD  
Richmond, Virginia

James E. Peacock, Jr., MD  
Winston-Salem, North Carolina

Frank S. Rhame, MD  
Minneapolis, Minnesota

William A. Rutala, PhD, MPH  
Chapel Hill, North Carolina

William E. Scheckler, MD  
Madison, Wisconsin

Robert J. Shannon, MSPH  
Boston, Massachusetts

Walter E. Stamm, MD  
Seattle, Washington

Charles W. Stratton, MD  
Nashville, Tennessee

Timothy R. Townsend, MD  
Baltimore, Maryland

William M. Valenti, MD  
Rochester, New York

James Veazey, MD  
Albany, New York

Kathy J. Wydra, RN  
Geneva, New York

## FOREIGN ADVISORY BOARD

Graham Ayliffe, MD, FRC Path.  
Birmingham, England

Professor G. Berencsi  
Szeged, Hungary

Professor Jaap Dankert  
Groningen, Netherlands

Professor Dr. F. Daschner  
Freiburg, West Germany

Lars O. Kallings, MD  
Stockholm, Sweden

Professor W.B. Kędzia  
Sieroca, Poland

Professor A.P. Krasilnikow  
Minsk, USSR

Professor Dr. W. Marget  
Munich, West Germany

Bertil Nyström, MD  
Huddinge, Sweden

Ian Phillips, MA, MD, MRC Path.  
London, England

Samuel Ponce de Leon, MD  
Mexico City, Mexico

Hans Reber, MD  
Basel, Switzerland

Professor Gerald Reybrouck  
Leuven, Belgium

Manfred L. Rotter, MD, DipBact  
Vienna, Austria

Theodore Sacks, MD  
Jerusalem, Israel

Dr. Bernhard M. Thimm  
Federal Republic of Germany

Professor Dr. med. H.P. Werner  
Mainz, West Germany

Professor Dr. W. Weuffen  
Greifswald, German Democratic Republic